Literature DB >> 16052585

Risk of malignancy in scleroderma: a population-based cohort study.

Soumya Chatterjee1, George W Dombi, Richard K Severson, Maureen D Mayes.   

Abstract

OBJECTIVE: To determine the incidence of cancer in patients with scleroderma (systemic sclerosis) and to compare those rates with cancer rates in the local population.
METHODS: Cancer risk in scleroderma patients in the Detroit metropolitan area was assessed by linking patient identification codes of the Michigan Scleroderma Registry to the Metropolitan Detroit Cancer Surveillance System database. Patients were screened between the years 1973 and 2002, with additional followup to 2004. Standardized incidence ratios (SIRs) were calculated for selected malignancies (lung, liver, colon, breast, cervical, and prostate cancers, and non-Hodgkin's lymphomas), with stratification by sex and race.
RESULTS: Of 934 patients in the Scleroderma Registry, 538 were included in the study based on tri-county residency (436 females and 102 males). Of these, 45 first malignancies were noted (37 females and 8 males). Lung cancer (10 cases) was found to be the most common cancer in scleroderma patients. However, its incidence was not significantly different from that in the general population of metropolitan Detroit (SIR 1.23). Other types of cancer were examined, and no significant differences were found as compared with the rates in the local population, with 1 exception: black females with scleroderma had significantly higher rates of liver cancer (SIR 45.8).
CONCLUSION: Contrary to previous studies, this study did not find statistical evidence of an increased incidence of cancer in scleroderma patients, except for liver cancer. One possible reason is the high background rates of certain cancers in the metropolitan Detroit area. It may be necessary to consider local cancer rates when comparing different scleroderma cohorts.

Entities:  

Mesh:

Year:  2005        PMID: 16052585     DOI: 10.1002/art.21225

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  38 in total

Review 1.  Pulmonary arterial hypertension associated with systemic sclerosis.

Authors:  Stephen C Mathai; Paul M Hassoun
Journal:  Expert Rev Respir Med       Date:  2011-04       Impact factor: 3.772

Review 2.  Lung involvement in systemic sclerosis.

Authors:  Paul M Hassoun
Journal:  Presse Med       Date:  2010-12-30       Impact factor: 1.228

Review 3.  Management of Esophageal Squamous Cell Carcinoma with Definitive Chemoradiotherapy in a Patient with Scleroderma: Case Report and Review of the Literature.

Authors:  David P Horowitz; Balazs Halmos; John Poneros; Joshua Sonett; Helen Remotti; Ryan J Burri
Journal:  J Gastrointest Cancer       Date:  2012-09

4.  Malignancy as a comorbidity in rheumatic diseases: a retrospective hospital-based study.

Authors:  Hai-Long Wang; Yong-Ming Zhou; Guang-Zhao Zhu; Zhu Yang; Bao-Jin Hua
Journal:  Clin Rheumatol       Date:  2017-05-16       Impact factor: 2.980

5.  Case of lung carcinoma revealed by vulvar metastasis associated with systemic scleroderma and literature review.

Authors:  Safae Mansouri; Luis A Glaria; Naim Asmae; Luis F Flores
Journal:  Rep Pract Oncol Radiother       Date:  2013-02-06

6.  Possible anti-metastatic effect of iloprost in a patient with systemic sclerosis with lung cancer: a case study.

Authors:  Yavuz Pehlivan; Ibrahim Halil Turkbeyler; Ozan Balakan; Alper Sevinc; Mustafa Yilmaz; Kemal Bakir; Ahmet Mesut Onat
Journal:  Rheumatol Int       Date:  2011-03-30       Impact factor: 2.631

7.  Refractory anemia in systemic sclerosis: myelodisplastic syndrome.

Authors:  Gökhan Sargın; Taşkın Şentürk; İrfan Yavaşoğlu
Journal:  Eur J Rheumatol       Date:  2015-03-31

8.  Malignancy in scleroderma patients from south west England: a population-based cohort study.

Authors:  Keith Siau; C J Laversuch; P Creamer; K P O'Rourke
Journal:  Rheumatol Int       Date:  2010-01-08       Impact factor: 2.631

9.  Rheumatic diseases and malignancies.

Authors:  Violeta Bojinca; Iustina Janta
Journal:  Maedica (Buchar)       Date:  2012-12

Review 10.  [Interdisciplinary point of contact between rheumatology and pneumology].

Authors:  J Hermann; G Kovacs; S Scheidl
Journal:  Z Rheumatol       Date:  2008-09       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.